Report LibraryAll Reports
Datamonitor Healthcare I&I Disease Analysis: Crohn's Disease
June 09, 2020Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn’s disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood. The disease course is characterized by periods of remission sporadically interspersed with inflammatory flares.
As specialty products, therapies for Crohn’s disease can be expensive, and formulary positioning is paramount to product uptake. Payers are settled in vital contracts that lead them to prioritize broad immunology drugs Humira and Remicade. This has posed a high barrier to newer entrants to the market, which cannot compete in volume and rebates. Biosimilar and generic competition will further undermine the likely premium pricing of newer drugs and pipeline products.
This Datamonitor Healthcare report contains a Disease Analysis module.
Inflammatory Bowel Disease (IBD)